|
Combination therapy for multidrug-resistant organisms: in vitro and clinical studies |
|||||
| Author, year |
In vitro/clinical study |
Setting/organism |
Susceptibility |
Therapy |
Outcome |
|
|
|||||
| Zuravleff et al. (1983) [48] |
In vitro study |
33 isolates of Pseudomonas aeruginosa |
All resistant to rifampin; 12 resistant to tobramycin alone; one resistant to ticarcillin alone; three resistant to tobramycin + ticarcillin |
Ticarcillin, tobramycin, plus rifampin |
In vitro efficacy against all 33 isolates |
| Yoon et al. (2004) [45] |
In vitro study |
8 isolates of Acinetobacter baumannii |
All resistant to all commonly used antibiotics |
Polymyxin B plus imipenem; polymyxin B plus rifampin; polymyxin B, imipenem, plus rifampin |
Double combinations were bactericidal for seven isolates and the triple combination was bactericidal for all eight isolates within 24 hours in vitro |
| Ostenson et al. (1977) [47] |
Clinical report |
Serious infections due to Serratia marcescens |
All resistant to polymyxin B and rifampin |
Polymyxin B plus rifampin |
Clinical and bacteriologic cure in eight out of 12 patients (67%) |
| Korvick et al. (1992) [46] |
Clinical study |
121 patients with P. aeruginosa bacteremia |
All organisms were susceptible to the β-lactam and aminoglycoside administered |
Randomized to three drugs (β-lactam, aminoglycoside, and rifampin; n = 58) or two drugs (β-lactam and aminoglycoside; n = 63) |
Bacteriologic cure was significantly greater with three drugs (57 patients [98%]) than with two drugs (54 patients [86%]; P = 0.018) |
Rahal Critical Care 2008 12(Suppl 4):S5 doi:10.1186/cc6821 |
|||||